HF Definition. Why and How Should We Be Treating Patients With Heart Failure With Preserved Ejection Fraction?

Slides:

Advertisements

Similar presentations

Heart Failure Whistle Stop Talks No 1 HFrEF and HFpEF Definitions for Diagnosis Susie Bowell BA Hons, RGN Heart Failure Specialist Nurse.

Advertisements

May 23rd, 2012 Hot topics from the Heart Failure Congress in Belgrade.

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults p.o.box zip code Done by: Dr.Amin Zagzoog.

Embargoed Until 3:45 p.m. ET, Sunday, Nov. 8, 2015

Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.

Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure with Preserved Ejection Fraction (RELAX): A Randomized.

Case-Based Examination of Treatment Options in Type 2 Diabetes Management.

Effect of Phosphodiesterase-5 Inhibition on Exercise

David M Kaye MD, PhD on behalf of the REDUCE LAP HF Investigators

SAVOR-TIMI 53 Summary SAVOR-TIMI 53: Primary End Point of CV Death, MI, Ischemic Stroke.

CLINICAL DILEMMAS IN HEART FAILURE:

Emerging Concepts in Heart Failure

Windhi Dwijanarko RSU DADI KELUARGA, PURWOKERTO

Introduction: Alarming Statistics Causes of Death in Prevalent Dialysis Patients,

A Randomized Clinical Trial

Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design Randomized, double-blind.

Heart Rate, HF Admissions, and Readmissions

A CASE CHALLENGE IN HFrEF:

Select Topics in Cardiovascular Medicine

Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy

Heart Failure Prevention: Mission Impossible?

T2DM and CV Outcomes Trials: A Deep Dive!

PAH Therapy Revisited.

Treating HFrEF: Challenges Faced

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Program Overview. Treatment Options for Post-MI patients with LVD – are all ACE Inhibitors Equal?

Selected Highlights of the Latest Advances in PAH

Tackling CV Risk in T2DM.

G. Michael Felker et al. JCHF 2014;2:

Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?

Type 2 Diabetes Management: Where Are We Heading in Our Efforts to Control CV Risk?

LEADER One Year On.

Using Heart Rate as a Biomarker in Clinical Practice.

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

ALBATROSS Trial design: Patients with MI without heart failure were randomized to an IV bolus of potassium canrenoate 200 mg as early as possible, then.

Challenging the Myths in Heart Failure With Reduced Ejection Fraction

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

ATHENA-HF Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone.

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

Reexamining the Basics of HFpEF

Pharmacotherapy for Diabetic Coronary Disease:

Managing HF in Primary Care

Updates From ACC.

Anaerobic threshold responder analysis

Iron Deficiency in Heart Failure

Add-On Therapy to Insulin in T1DM Management

The Rising Crisis of Prediabetes Diagnosis and Management of the Patient With Prediabetes.

Program Goals Background: Anticoagulation in Patients With VTE.

Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

DECLARE-TIMI 58.

Perspective on the Multidisciplinary Management of PAH

Background. Current Perspectives on the Management of Iron Deficiency in Chronic Heart Failure.

HF-Related Hospitalization and Readmissions

Transitioning Therapy in PAH: Practical Strategies and Considerations

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

Uptitration of Medications in HF: Start Low but Aim High and Stay High

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Steven R. Steinhubl, and Eric J. Topol JACC 2015;66:

In-Hospital Treatment for Heart Failure: New Approaches and a Renewed Sense of Hope?

What's New in Oral Combination Therapy for Type 2 Diabetes?

Managing HF in Primary Care

Percentage distribution of ESC HF subtypes and no cardiac dysfunction (no dysf, n=38) among all 370 included patients, where HFvhd is HF due to valvular.

My PAH Patient.

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

Top Tips in Evidence-Based Care for HFrEF

Key Data on Improving Outcomes in HF Patients

Diagnosing HFpEF: What Every Cardiologist Needs to Know

Presentation transcript:

Why and How Should We Be Treating Patients With Heart Failure With Preserved Ejection Fraction?

HF Definition

HFpEF

Outcomes of HFpEF

Why Is HFpEF So Difficult to Diagnose?

Framingham HF Criteria

Echocardiography Criteria for HFpEF

Phenotypes in HFpEF Based on Predisposition and Presentation

Obese HFpEF phenotype

HFpEF Predisposition Phenotypes: PAH and RV Failure

How Do You Evaluate a Patient for HFpEF?

Stress Testing

Workup Specific to Phenotype … Does It Differ?

H2FPEF Scoring

ESC HFpEF Consensus: Diagnostic Algorithm

Diagnosis: HFpEF … How Should It Be Treated?

CHAMPION Trial: Treatment of Congestion With Diuretics

TOPCAT: Primary Outcome (CV Death, HHF, or Resuscitated Cardiac Arrest)

TOPCAT Regional Data: Benefit of Spironolactone

US Guidelines: Use of MRAs in HFpEF

HFpEF: Management of Comorbidities

Management of Hypertension in HFpEF

Management of Ischemia and HFpEF

AF and HFpEF

Preference of Heart Rate in HFpEF

Exercise and Diet Improve Peak VO2 and KCCQ in HFpEF

PARAGON HF

HFpEF Interventional Strategies: Interatrial Shunt and Pericardiectomy

Two HFpEF Outcomes Trials With SGLT2 Inhibitors

NEAT-HFpEF: Trend Toward Lower Activity Level With Nitrates (Including 6MWT, QOL, NT-proBNP)

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)